Capital raised by leading RNA-based private biopharma companies worldwide 2020
In 2020, Abogen Biosciences reported that it raised around 817.5 million U.S. dollars in capital funding, while Laronde reported around 490 million U.S. dollars raised. This statistic illustrates the total capital raised by leading private RNA-based biopharmaceutical companies worldwide in 2020, in million U.S. dollars.